ISSN: 1305-385X
Hakkında: Özel sayılar şeklinde yayınlanır.
|
|
|
Following And Treatment Of Anaemia On Hemodialysis
Dr. Mehdi YEKSAN,a Dr. İbrahim GÜNEYa
aNefroloji BD, Selçuk Ünversitesi Meram Tıp Fakültesi, KONYA
Anaemia is a frequent complication of choronic kidney disease (CKD), and it is reported that anaemia’s prevalence has been shown to increase with diminishing renal function. In the guidelines, an anaemia work-up should be initiated in patients with chronic kidney disease when the Hgb <11 g/dL (Hct <33%) in pre-menopausal females and Hgb <12g/dL (Hct is <37%) in adult males and post-menopausal females. The most important reason for a progressive decline in Hgb concentrations in patients with CKD is probably a relative deficiency of erythropoietin. In the guidelines, an initial clinical and laboratory evaluation should be completed prior to considering the commencement of treatment with an erythropoiesis-stimulating agent (ESA) in patients with CKD, to evaluate possible causes of anaemia superimposed on relative erythropoietin deficiency. It is suggested that target Hgb levels for anemia treatment are 11-12 g/dl (Hct 33-36%) in both the European Best Practice Gidelines and the K/DOQI Guidelines. It is important erythropoietin and iron treatment with making good quality heamodialysis, diagnosis and treatment of inflamatuary causes like occult infection and early diagnosis and treatment of malnutrition, to reach this targets.Keywords: Anaemia, heamodialysis, erythropoietin treatment, iron treatmentTurkiye Klinikleri J Int Med Sci 2006, 2(4):48-54
|
|
|
|
|
